The $70M upfront cash infusion and debt paydown significantly strengthen Pacira's balance sheet, removing a potential overhang. The revenue milestones provide upside optionality through 2031. Watch for Q3 2026 close and subsequent 10-Q for debt reduction details and updated guidance reflecting the streamlined biopharma focus. The spasticity program collaboration adds an incremental catalyst path.
Price Chart
Executive Summary
Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Biomet for up to $140M in total consideration ($70M upfront cash plus up to $70M in future revenue-based milestones). The deal includes collaboration on a spasticity program. Proceeds will be used to repay Pacira's senior secured revolving credit facility, strengthening its balance sheet. This divestiture advances Pacira's transition into a pure biopharmaceutical company focused on non-opioid therapies.
Key Financial Metrics
Key Facts
- Pacira to receive $70M upfront cash for the iovera divestiture to Zimmer Biomet
- Total potential consideration up to $140M including $70M in revenue-based milestone payments through 2031
- Upfront proceeds to be used to pay down Pacira's senior secured revolving credit facility
- 66 employees (~8% of workforce) expected to transfer to Zimmer Biomet at closing
- Transaction expected to close in Q3 2026, subject to customary conditions
- Pacira and Zimmer Biomet will collaborate on advancing the spasticity program, with potential incremental compensation for Pacira upon successful study and regulatory approval
Financial Impact
Up to $140M total consideration ($70M upfront) for iovera divestiture, with upfront cash used to reduce debt
Risk Factors
- Revenue milestones of up to $70M are contingent on iovera commercial performance and may not be achieved
- Transaction requires customary closing conditions and may be delayed or terminated
- Execution risk in transitioning 66 employees and related operations to Zimmer Biomet
- Removal of iovera revenue stream could pressure near-term reported revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-046136 |
| Exhibit: exhibit991-ioverapressrele.htm | 0001628280-26-046136 |
| Document: 0001628280-26-046136-index-headers.html | 0001628280-26-046136 |
| Document: 0001628280-26-046136-index.html | 0001628280-26-046136 |
| Document: 0001628280-26-046136.txt | 0001628280-26-046136 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access